+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Chronic Idiopathic Constipation Therapeutic Market - Global Forecast 2026-2032- Product Image
Chronic Idiopathic Constipation Therapeutic Market - Global Forecast 2026-2032- Product Image
Sale

Chronic Idiopathic Constipation Therapeutic Market - Global Forecast 2026-2032

  • Report

  • 182 Pages
  • August 2026
  • Region: Global
  • 360iResearch™
  • ID: 6010861
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Chronic Idiopathic Constipation Therapeutic Market is projected to reach USD 1.48 Billion in 2026. It is expected to continue growing at a CAGR of 7.93%, reaching USD 2.35 Billion by 2032.

Chronic idiopathic constipation (CIC) is a persistent disorder marked by infrequent bowel movements, difficult stool passage, straining, hard stools, or a sensation of incomplete evacuation without an identifiable structural, metabolic, or medication-related cause. Defined through symptom-based criteria such as Rome IV and evaluated through guideline-directed clinical assessment, CIC is a high-burden functional gastrointestinal disorder associated with impaired quality of life, reduced work productivity, recurring physician visits, and ongoing use of nonprescription and prescription therapies.

The chronic idiopathic constipation therapeutic landscape is anchored by a stepwise treatment model that begins with dietary fiber, hydration, physical activity, and lifestyle optimization, followed by over-the-counter osmotic and stimulant laxatives for symptom relief. For patients with inadequate response, prescription therapies include chloride channel activators such as lubiprostone, guanylate cyclase-C agonists such as linaclotide and plecanatide, selective 5-HT4 agonists such as prucalopride, and regionally approved agents used for chronic constipation. Adoption is supported by aging populations, improved recognition of disorders of gut-brain interaction, expanding gastroenterology access, and stronger use of evidence-based treatment pathways for refractory constipation.

Transformative Shifts in the CIC Therapeutics Landscape

The CIC treatment landscape is shifting from episodic symptom relief toward personalized, mechanism-based care. Clinical guidance from major gastroenterology societies increasingly emphasizes matching therapy to symptom severity, prior treatment response, tolerability, comorbidities, safety profile, and patient preferences. This has strengthened the role of prescription chronic idiopathic constipation therapies for patients who do not achieve sustained relief with fiber, polyethylene glycol, lactulose, or stimulant laxatives.

Commercial dynamics are also changing as payer scrutiny, generic availability, formulary management, and value-based access reshape prescribing behavior. At the same time, innovation is moving beyond complete spontaneous bowel movements alone toward abdominal symptoms, bloating, straining, stool consistency, rescue medication use, adherence, and patient-reported outcomes. Products and strategies that demonstrate durable efficacy, tolerability, convenient dosing, persistence, and real-world value are best positioned in the chronic idiopathic constipation therapeutic market.

Cumulative Impact of Artificial Intelligence on CIC Care

Artificial intelligence is beginning to influence the CIC therapeutic ecosystem across drug discovery, clinical development, diagnosis support, and patient engagement. AI-enabled analytics can help identify responder subgroups in clinical trial datasets, model gut motility and secretion pathways, and support biomarker exploration for constipation phenotypes currently classified as idiopathic. These capabilities are particularly relevant because CIC is heterogeneous and may overlap with slow-transit constipation, pelvic floor dysfunction, medication effects, and disorders of gut-brain interaction.

In clinical and commercial settings, AI can improve care pathways by analyzing electronic health records, pharmacy claims, symptom diaries, and patient-reported outcomes to detect inadequate treatment response earlier. Digital tools may help support escalation from OTC agents to prescription therapies, adherence monitoring, adverse event detection, and longitudinal symptom tracking. The cumulative impact is a gradual move toward precision gastroenterology, provided stakeholders address clinical validation, data privacy, algorithmic bias, interoperability, and regulatory expectations.

Key Regional Insights Across Global CIC Therapeutic Markets

North America remains one of the most mature regions for chronic idiopathic constipation therapeutics due to established diagnostic pathways, broad availability of OTC and prescription options, and high awareness among primary care clinicians and gastroenterologists. The United States supports innovation and branded prescription uptake through multiple approved therapeutic classes and strong specialist access, while Canada reflects guideline-driven care and formulary-led reimbursement decisions that influence treatment sequencing.

Europe shows steady demand supported by aging demographics, national health systems, and evidence-based gastroenterology practice, although reimbursement requirements and country-level access pathways vary across the region. Asia-Pacific is gaining strategic importance as China, Japan, India, South Korea, and Australia experience expanding health care access, aging populations, urban lifestyles, and broader recognition of functional gastrointestinal disorders. Japan is particularly notable for regional experience with constipation pharmacotherapy, including agents such as elobixibat for chronic constipation.

Latin America, the Middle East, and Africa present long-term opportunities tied to urbanization, retail pharmacy access, improved specialist availability, and rising awareness of chronic gastrointestinal symptoms. However, affordability constraints, underdiagnosis, uneven reimbursement, and differences in primary care referral pathways can limit adoption of premium prescription CIC therapeutics. Across these regions, clinician education, access to validated laxatives, better symptom recognition, and clear escalation protocols remain central to therapeutic development.

Key Group Insights for CIC Therapeutic Adoption

Within ASEAN, expanding private health care systems, growing retail pharmacy networks, and increasing gastroenterology awareness are improving access to constipation therapies, although prescription adoption remains sensitive to out-of-pocket spending and variable reimbursement. GCC markets benefit from comparatively strong health expenditure, specialist access, digital health investment, and chronic disease management infrastructure, supporting demand for branded gastrointestinal therapies where formulary coverage and patient affordability align.

The European Union provides a structured environment for clinical evidence generation, pharmacovigilance, regulatory oversight, and health technology assessment, making real-world effectiveness, safety, and cost-effectiveness important for chronic idiopathic constipation therapeutic access. BRICS countries offer significant patient reach and long-term adoption potential, led by China, India, and Brazil, but require localized pricing, distribution strength, physician education, and evidence packages aligned with public and private payer expectations.

G7 markets remain central for product launches, guideline influence, clinical research activity, and premium therapy adoption because of advanced regulatory systems, high treatment awareness, and mature gastroenterology networks. NATO member markets overlap substantially with North America and Europe, where regulatory alignment, pharmaceutical distribution capacity, supply chain resilience, and established health care infrastructure support dependable access to CIC therapeutics.

Key Country Insights Shaping CIC Therapeutic Demand

The United States is a leading country market for chronic idiopathic constipation therapeutics because of multiple FDA-approved prescription options, broad OTC availability, active disease awareness, high specialist utilization, and established payer processes for step therapy and prior authorization. Canada follows a more reimbursement-disciplined model shaped by public and private formularies, while Mexico and Brazil show growth through private care, retail pharmacy channels, urban health care access, and increasing recognition of functional bowel disorders.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine aging populations with guideline-oriented management of chronic constipation, although national reimbursement policies and prescribing rules shape the pace of branded therapy adoption. Russia maintains demand for constipation management, but access, affordability, and supply reliability remain important considerations for consistent availability of CIC therapeutics.

China and India offer substantial patient reach as diagnosis improves, urban populations seek care for chronic gastrointestinal symptoms, and hospital-based gastroenterology services expand. Japan and South Korea benefit from aging demographics, advanced health systems, and strong clinical awareness of chronic constipation, with Japan showing notable experience in regionally established constipation pharmacotherapy. Australia represents a developed, guideline-oriented market with strong primary care infrastructure, specialist referral networks, and access to both OTC and prescription treatment options.

Actionable Recommendations for CIC Therapeutic Leaders

Industry leaders should prioritize differentiated clinical evidence that goes beyond bowel movement frequency to include straining, stool consistency, bloating, abdominal discomfort, rescue medication use, treatment satisfaction, and quality-of-life endpoints. Real-world evidence programs can strengthen payer and clinician discussions by demonstrating persistence, tolerability, reduced health care utilization, and improved patient-reported outcomes among patients who do not achieve adequate relief with OTC therapy.

Organizations should localize market access strategies by aligning pricing, evidence packages, reimbursement submissions, and education initiatives with regional health system realities. Partnerships with gastroenterology societies, primary care networks, digital health platforms, and pharmacy channels can accelerate diagnosis, appropriate treatment escalation, and patient adherence. AI-enabled symptom tracking and adherence tools should be deployed only within validated clinical workflows supported by transparent data governance, privacy safeguards, and measurable patient benefit.

Research Methodology for the CIC Therapeutics Analysis

This executive summary is built on a secondary research framework that synthesizes publicly available evidence from regulatory agencies, clinical practice guidelines, peer-reviewed gastroenterology literature, prescribing information, pharmacovigilance resources, and market access intelligence. Sources include regulatory information from agencies such as the FDA and EMA, professional society guidance, and published evidence on chronic constipation epidemiology, disease burden, treatment pathways, and therapeutic outcomes.

The analysis applies triangulation across clinical, commercial, regional, group-level, and country-level indicators to identify durable strategic themes. Therapeutic classes and adoption dynamics were assessed through the lenses of disease burden, approved treatment availability, reimbursement environment, health care infrastructure, prescribing behavior, patient access, and barriers to escalation. Findings are presented as strategic industry insights and should not be interpreted as individual medical advice.

Conclusion: Strategic Outlook for CIC Therapeutics

The chronic idiopathic constipation therapeutic landscape is evolving from conventional laxative-centered management toward more personalized, evidence-based care supported by prescription innovation, patient-reported outcomes, and digital health capabilities. As diagnosis improves, populations age, and functional gastrointestinal disorders receive greater clinical attention, demand for effective CIC therapies is expected to remain resilient across developed and emerging health care systems.

Future leadership in chronic idiopathic constipation therapeutics will depend on clinical differentiation, access strategy, regional execution, and responsible use of AI to improve patient identification and treatment optimization. Organizations that combine strong evidence with affordability, physician education, pharmacy engagement, and patient-centered support will be well positioned to advance care and strengthen adoption in CIC therapeutics.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. New Revenue Opportunities
3.5. Next-Generation Business Models
3.6. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Chronic Idiopathic Constipation Therapeutic Market, by Treatment Modality
7.1. Introduction
7.2. Non-Pharmacological / Adjunct
7.3. Pharmacological
8. Chronic Idiopathic Constipation Therapeutic Market, by Drug Class
8.1. Introduction
8.2. Guanylate Cyclase-C (GC-C) Agonists
8.3. Osmotic Laxatives
8.4. Stimulant Laxatives
8.5. Serotonin 5-HT4 Receptor Agonists
8.6. Bulking Agents
8.7. Stool Softeners
9. Chronic Idiopathic Constipation Therapeutic Market, by Formulation Type
9.1. Introduction
9.2. Solid Oral Formulations
9.2.1. Tablets
9.2.2. Capsules
9.3. Liquid Oral Formulations
9.3.1. Solutions
9.3.2. Suspensions
9.4. Rectal Formulations
9.4.1. Suppositories
9.4.2. Enemas
10. Chronic Idiopathic Constipation Therapeutic Market, by Route Of Administration
10.1. Introduction
10.2. Rectal
10.3. Oral
11. Chronic Idiopathic Constipation Therapeutic Market, by Prescription Status
11.1. Introduction
11.2. Over-the-Counter (OTC) Medicines
11.3. Prescription Medicines
12. Chronic Idiopathic Constipation Therapeutic Market, by End User
12.1. Introduction
12.2. Hospitals
12.3. Specialty Gastroenterology Clinics
12.4. Primary Care Clinics
12.5. Home Care Settings
12.6. Long Term Care Facilities
12.7. Rehabilitation Centers
13. Chronic Idiopathic Constipation Therapeutic Market, by Distribution Channel
13.1. Introduction
13.2. Hospital Pharmacies
13.3. Online Pharmacies
13.4. Retail Pharmacies
14. Chronic Idiopathic Constipation Therapeutic Market, by Age Group
14.1. Introduction
14.2. Pediatric Patients
14.3. Adult Patients
15. Chronic Idiopathic Constipation Therapeutic Market, by Region
15.1. Europe
15.2. Asia-Pacific
15.3. North America
15.4. Latin America
15.5. Africa
15.6. Middle East
16. Chronic Idiopathic Constipation Therapeutic Market, by Group
16.1. NATO
16.2. G7
16.3. European Union
16.4. BRICS
16.5. ASEAN
16.6. GCC
17. Chronic Idiopathic Constipation Therapeutic Market, by Country
17.1. United States
17.2. China
17.3. Germany
17.4. United Kingdom
17.5. Canada
17.6. Japan
17.7. India
17.8. France
17.9. Brazil
17.10. Mexico
17.11. Italy
17.12. Russia
17.13. Australia
17.14. Spain
17.15. South Korea
18. Competitive Landscape
18.1. Market Share Analysis, 2025
18.2. FPNV Positioning Matrix, 2025
18.3. Market Concentration Analysis, 2025
18.3.1. Concentration Ratio (CR)
18.3.2. Herfindahl Hirschman Index (HHI)
18.4. Recent Developments & Impact Analysis, 2025
18.5. Product Portfolio Analysis, 2025
18.6. Benchmarking Analysis, 2025
19. Company Profiles
19.1. AbbVie Inc.
19.2. Albireo Pharma, Inc. by Ipsen S.A.
19.3. ANI Pharmaceuticals, Inc.
19.4. Ardelyx Inc.
19.5. Bausch Health Companies Inc.
19.6. Bayer AG
19.7. Dr. Reddy’s Laboratories Ltd.
19.8. Eisai Co., Ltd.
19.9. Ferring B.V.
19.10. Ironwood Pharmaceuticals, Inc.
19.11. Lupin Limited
19.12. Mallinckrodt plc
19.13. MSN Laboratories Private Limited
19.14. Norgine B.V.
19.15. Sanofi S.A.
19.16. Shionogi & Co., Ltd.
19.17. Takeda Pharmaceutical Company Limited
19.18. Zydus Cadila Limited
List of Figures
FIGURE 1. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET, YEARS CONSIDERED FOR THE STUDY
FIGURE 2. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET, RESEARCH DESIGN
FIGURE 3. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET, RESEARCH FRAMEWORK
FIGURE 4. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET, DATA TRIANGULATION
FIGURE 5. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, 2024-2032 (USD MILLION)
FIGURE 6. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2025 VS 2032 (%)
FIGURE 7. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 8. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
FIGURE 9. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 10. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2025 VS 2032 (%)
FIGURE 11. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 12. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2032 (%)
FIGURE 13. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 14. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2025 VS 2032 (%)
FIGURE 15. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 16. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2025 VS 2032 (%)
FIGURE 17. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 18. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
FIGURE 19. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 20. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2025 VS 2032 (%)
FIGURE 21. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 22. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY REGION, 2025 VS 2032 (%)
FIGURE 23. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 24. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
FIGURE 25. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 26. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
FIGURE 27. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
FIGURE 28. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SHARE, BY KEY PLAYER, 2025
FIGURE 29. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025
List of Tables
TABLE 1. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SEGMENTATION & COVERAGE
TABLE 2. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 3. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 4. GLOBAL NON-PHARMACOLOGICAL / ADJUNCT MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 5. GLOBAL NON-PHARMACOLOGICAL / ADJUNCT MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 6. GLOBAL NON-PHARMACOLOGICAL / ADJUNCT MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 7. GLOBAL PHARMACOLOGICAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 8. GLOBAL PHARMACOLOGICAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 9. GLOBAL PHARMACOLOGICAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 10. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 11. GLOBAL GUANYLATE CYCLASE-C (GC-C) AGONISTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 12. GLOBAL GUANYLATE CYCLASE-C (GC-C) AGONISTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 13. GLOBAL GUANYLATE CYCLASE-C (GC-C) AGONISTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 14. GLOBAL OSMOTIC LAXATIVES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 15. GLOBAL OSMOTIC LAXATIVES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 16. GLOBAL OSMOTIC LAXATIVES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 17. GLOBAL STIMULANT LAXATIVES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 18. GLOBAL STIMULANT LAXATIVES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 19. GLOBAL STIMULANT LAXATIVES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 20. GLOBAL SEROTONIN 5-HT4 RECEPTOR AGONISTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 21. GLOBAL SEROTONIN 5-HT4 RECEPTOR AGONISTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 22. GLOBAL SEROTONIN 5-HT4 RECEPTOR AGONISTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 23. GLOBAL BULKING AGENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 24. GLOBAL BULKING AGENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 25. GLOBAL BULKING AGENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 26. GLOBAL STOOL SOFTENERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 27. GLOBAL STOOL SOFTENERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 28. GLOBAL STOOL SOFTENERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 29. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 30. GLOBAL SOLID ORAL FORMULATIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 31. GLOBAL SOLID ORAL FORMULATIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 32. GLOBAL SOLID ORAL FORMULATIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 33. GLOBAL TABLETS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 34. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 35. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 36. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 37. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 38. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 39. GLOBAL LIQUID ORAL FORMULATIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 40. GLOBAL LIQUID ORAL FORMULATIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 41. GLOBAL LIQUID ORAL FORMULATIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 42. GLOBAL SOLUTIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 43. GLOBAL SOLUTIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 44. GLOBAL SOLUTIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 45. GLOBAL SUSPENSIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 46. GLOBAL SUSPENSIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 47. GLOBAL SUSPENSIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 48. GLOBAL RECTAL FORMULATIONS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 49. GLOBAL RECTAL FORMULATIONS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 50. GLOBAL RECTAL FORMULATIONS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 51. GLOBAL SUPPOSITORIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 52. GLOBAL SUPPOSITORIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 53. GLOBAL SUPPOSITORIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 54. GLOBAL ENEMAS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 55. GLOBAL ENEMAS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 56. GLOBAL ENEMAS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 57. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 58. GLOBAL RECTAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 59. GLOBAL RECTAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 60. GLOBAL RECTAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 61. GLOBAL ORAL MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 62. GLOBAL ORAL MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 63. GLOBAL ORAL MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 64. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 65. GLOBAL OVER-THE-COUNTER (OTC) MEDICINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 66. GLOBAL OVER-THE-COUNTER (OTC) MEDICINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 67. GLOBAL OVER-THE-COUNTER (OTC) MEDICINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 68. GLOBAL PRESCRIPTION MEDICINES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 69. GLOBAL PRESCRIPTION MEDICINES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 70. GLOBAL PRESCRIPTION MEDICINES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 71. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 72. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 73. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 74. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 75. GLOBAL SPECIALTY GASTROENTEROLOGY CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 76. GLOBAL SPECIALTY GASTROENTEROLOGY CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 77. GLOBAL SPECIALTY GASTROENTEROLOGY CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 78. GLOBAL PRIMARY CARE CLINICS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 79. GLOBAL PRIMARY CARE CLINICS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 80. GLOBAL PRIMARY CARE CLINICS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 81. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 82. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 83. GLOBAL HOME CARE SETTINGS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 84. GLOBAL LONG TERM CARE FACILITIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 85. GLOBAL LONG TERM CARE FACILITIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 86. GLOBAL LONG TERM CARE FACILITIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 87. GLOBAL REHABILITATION CENTERS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 88. GLOBAL REHABILITATION CENTERS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 89. GLOBAL REHABILITATION CENTERS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 90. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 91. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 92. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 93. GLOBAL HOSPITAL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 94. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 95. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 96. GLOBAL ONLINE PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 97. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 98. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 99. GLOBAL RETAIL PHARMACIES MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 100. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 101. GLOBAL PEDIATRIC PATIENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 102. GLOBAL PEDIATRIC PATIENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 103. GLOBAL PEDIATRIC PATIENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 104. GLOBAL ADULT PATIENTS MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 105. GLOBAL ADULT PATIENTS MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 106. GLOBAL ADULT PATIENTS MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 107. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 108. EUROPE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 109. EUROPE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 110. EUROPE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 111. EUROPE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 112. EUROPE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 113. EUROPE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 114. EUROPE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 115. EUROPE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 116. EUROPE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 117. EUROPE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 118. EUROPE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 119. EUROPE CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 120. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 121. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 122. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 123. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 124. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 125. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 126. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 127. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 128. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 129. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 130. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 131. ASIA-PACIFIC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 132. NORTH AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 133. NORTH AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 134. NORTH AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 135. NORTH AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 136. NORTH AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 137. NORTH AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 138. NORTH AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 139. NORTH AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 140. NORTH AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 141. NORTH AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 142. NORTH AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 143. NORTH AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 144. LATIN AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 145. LATIN AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 146. LATIN AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 147. LATIN AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 148. LATIN AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 149. LATIN AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 150. LATIN AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 151. LATIN AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 152. LATIN AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 153. LATIN AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 154. LATIN AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 155. LATIN AMERICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 156. AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 157. AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 158. AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 159. AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 160. AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 161. AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 162. AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 163. AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 164. AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 165. AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 166. AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 167. AFRICA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 168. MIDDLE EAST CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY REGION, 2017-2032 (USD MILLION)
TABLE 169. MIDDLE EAST CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 170. MIDDLE EAST CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 171. MIDDLE EAST CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 172. MIDDLE EAST CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 173. MIDDLE EAST CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 174. MIDDLE EAST CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 175. MIDDLE EAST CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 176. MIDDLE EAST CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 177. MIDDLE EAST CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 178. MIDDLE EAST CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 179. MIDDLE EAST CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 180. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 181. NATO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 182. NATO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 183. NATO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 184. NATO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 185. NATO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 186. NATO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 187. NATO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 188. NATO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 189. NATO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 190. NATO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 191. NATO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 192. NATO CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 193. G7 CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 194. G7 CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 195. G7 CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 196. G7 CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 197. G7 CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 198. G7 CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 199. G7 CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 200. G7 CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 201. G7 CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 202. G7 CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 203. G7 CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 204. G7 CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 205. EUROPEAN UNION CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 206. EUROPEAN UNION CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 207. EUROPEAN UNION CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 208. EUROPEAN UNION CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 209. EUROPEAN UNION CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 210. EUROPEAN UNION CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 211. EUROPEAN UNION CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 212. EUROPEAN UNION CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 213. EUROPEAN UNION CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 214. EUROPEAN UNION CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 215. EUROPEAN UNION CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 216. EUROPEAN UNION CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 217. BRICS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 218. BRICS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 219. BRICS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 220. BRICS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 221. BRICS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 222. BRICS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 223. BRICS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 224. BRICS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 225. BRICS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 226. BRICS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 227. BRICS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 228. BRICS CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 229. ASEAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 230. ASEAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 231. ASEAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 232. ASEAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 233. ASEAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 234. ASEAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 235. ASEAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 236. ASEAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 237. ASEAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 238. ASEAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 239. ASEAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 240. ASEAN CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 241. GCC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY GROUP, 2017-2032 (USD MILLION)
TABLE 242. GCC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 243. GCC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 244. GCC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 245. GCC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 246. GCC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 247. GCC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 248. GCC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 249. GCC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 250. GCC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 251. GCC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 252. GCC CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 253. GLOBAL CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY COUNTRY, 2017-2032 (USD MILLION)
TABLE 254. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 255. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 256. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 257. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 258. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 259. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 260. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 261. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 262. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 263. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 264. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 265. UNITED STATES CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 266. CHINA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 267. CHINA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 268. CHINA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 269. CHINA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 270. CHINA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 271. CHINA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 272. CHINA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 273. CHINA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 274. CHINA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 275. CHINA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 276. CHINA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 277. CHINA CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 278. GERMANY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 279. GERMANY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 280. GERMANY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 281. GERMANY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 282. GERMANY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 283. GERMANY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 284. GERMANY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 285. GERMANY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 286. GERMANY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 287. GERMANY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 288. GERMANY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DISTRIBUTION CHANNEL, 2017-2032 (USD MILLION)
TABLE 289. GERMANY CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY AGE GROUP, 2017-2032 (USD MILLION)
TABLE 290. UNITED KINGDOM CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, 2017-2032 (USD MILLION)
TABLE 291. UNITED KINGDOM CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY TREATMENT MODALITY, 2017-2032 (USD MILLION)
TABLE 292. UNITED KINGDOM CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY DRUG CLASS, 2017-2032 (USD MILLION)
TABLE 293. UNITED KINGDOM CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY FORMULATION TYPE, 2017-2032 (USD MILLION)
TABLE 294. UNITED KINGDOM CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY SOLID ORAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 295. UNITED KINGDOM CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY LIQUID ORAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 296. UNITED KINGDOM CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY RECTAL FORMULATIONS, 2017-2032 (USD MILLION)
TABLE 297. UNITED KINGDOM CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2017-2032 (USD MILLION)
TABLE 298. UNITED KINGDOM CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY PRESCRIPTION STATUS, 2017-2032 (USD MILLION)
TABLE 299. UNITED KINGDOM CHRONIC IDIOPATHIC CONSTIPATION THERAPEUTIC MARKET SIZE, BY END USER, 2017-2032 (USD MILLION)
TABLE 300. UN

Companies Mentioned

  • AbbVie Inc.
  • Albireo Pharma, Inc. by Ipsen S.A.
  • ANI Pharmaceuticals, Inc.
  • Ardelyx Inc.
  • Bausch Health Companies Inc.
  • Bayer AG
  • Dr. Reddy’s Laboratories Ltd.
  • Eisai Co., Ltd.
  • Ferring B.V.
  • Ironwood Pharmaceuticals, Inc.
  • Lupin Limited
  • Mallinckrodt plc
  • MSN Laboratories Private Limited
  • Norgine B.V.
  • Sanofi S.A.
  • Shionogi & Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Zydus Cadila Limited

Table Information

Report AttributeDetails
No. of Pages182
PublishedAugust 2026
Forecast Period2026 - 2032
Estimated Market Value ( USD ) in 2026 $ 1.48 Billion
Forecasted Market Value ( USD ) by 2032 $ 2.35 Billion
Compound Annual Growth Rate7.9%
Regions CoveredGlobal
No. of Companies Mentioned18

Related Topics

Related Reports

Chronic Idiopathic Constipation - Market Insights, Epidemiology, and Market Forecast - 2034 - Product Image

Chronic Idiopathic Constipation - Market Insights, Epidemiology, and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Chronic Idiopathic Constipation Therapeutic Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031 - Product Image

Chronic Idiopathic Constipation Therapeutic Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

  • Report
  • 180 Pages
  • Global
From
Constipation Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Constipation Treatment - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 120 Pages
  • Global
From
Chronic Idiopathic Constipation (CIC) Epidemiology Forecast 2026-2035 - Product Image

Chronic Idiopathic Constipation (CIC) Epidemiology Forecast 2026-2035

  • Report
  • 100 Pages
  • Global
From
Constipation Treatment Market Report 2026 - Product Image

Constipation Treatment Market Report 2026

  • Report
  • 250 Pages
  • Global
From

About the Chronic Idiopathic Constipation Drugs Market

Within the realm of gastrointestinal drugs, a distinct segment is dedicated to the treatment of Chronic Idiopathic Constipation (CIC), a prevalent condition characterized by infrequent bowel movements, difficulty in stool passage, or a sense of incomplete evacuation without an identifiable cause. The market for CIC medications includes a range of therapeutic options that aim to alleviate symptoms and improve patients' quality of life. These pharmacologic treatments largely consist of laxatives, stool softeners, prokinetic agents, chloride channel activators, guanylate cyclase-C agonists, and serotonin 5-HT4 receptor agonists, each targeting different aspects of the complex gastrointestinal function to induce bowel movements or enhance stool consistency. Development in this sector is driven by a combination of factors, including advancing understanding of gut motility and the nervous system, patient need, and innovation in drug design and delivery mechanisms. Several companies have established prominence in the Chronic Idiopathic Constipation Drugs market through the development and commercialization of effective treatments. Leading this niche are pharmaceutical firms such as Ironwood Pharmaceuticals, Takeda Pharmaceutical Company, Synergy Pharmaceuticals, Ardelyx, Pfizer, and Allergan. These companies offer a diverse portfolio of products and continue to invest in research and development to improve therapeutic outcomes and address unmet medical needs within the discipline of gastrointestinal health. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.